Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Sign Up to like & getrecommendations! Published in 2018 at "Academic radiology"
DOI: 10.1016/j.acra.2017.10.018
Abstract: RATIONALE AND OBJECTIVE The objective of this study was to analyze prognostic factors for survival after transarterial chemoembolization (TACE) combined with sorafenib for hepatocellular carcinoma (HCC) of Barcelona Clinic Liver Cancer (BCLC) stages B and… read more here.
Keywords: combined sorafenib; sorafenib treatment; prognostic factors; bclc stage ... See more keywords
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology Research"
DOI: 10.1111/hepr.13801
Abstract: Tyrosine kinase inhibitors target transarterial chemoembolization (TACE)‐mediated vascular endothelial growth factor to inhibit tumor revascularization and to slow tumor progression. The present study aimed to compare the clinical outcomes of TACE combined with lenvatinib (TACE‐lenvatinib)… read more here.
Keywords: chemoembolization; unresectable hepatocellular; combined lenvatinib; combined sorafenib ... See more keywords
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
Sign Up to like & getrecommendations! Published in 2022 at "BMC Cancer"
DOI: 10.1186/s12885-022-09173-4
Abstract: Background Vascular endothelial growth factor (VEGF) plays a role in the tumor microenvironment. Sorafenib, which inhibits the VEGF pathway, has an immune-modulation function but lacks substantial clinical data. This study aims to explore the efficacy… read more here.
Keywords: propensity score; study; advanced hepatocellular; anti combined ... See more keywords
In vivo inhibitory effect of suberoylanilide hydroxamic acid combined with sorafenib on human hepatocellular carcinoma cells
Sign Up to like & getrecommendations! Published in 2020 at "Brazilian Journal of Pharmaceutical Sciences"
DOI: 10.1590/s2175-97902019000318254
Abstract: The present study aimed to investigate the in vivo inhibitory effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) combined with sorafenib on human hepatocellular carcinoma HCCLM3 cells. The nude mice transplanted with HCCLM3 cells… read more here.
Keywords: combined sorafenib; sorafenib human; hydroxamic acid; inhibitory effect ... See more keywords
Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s248850
Abstract: Purpose Transcatheter arterial chemoembolization (TACE) and targeted therapy have become common methods in the treatment of advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the safety and efficacy of TACE combined… read more here.
Keywords: bclc stage; tace sorafenib; tace; group ... See more keywords